Stock Code: 000028/200028 Notice No.: 2022-36
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Semi-Annual Report 2022
I. Important Notice
The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors should
carefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and Shenzhen
Stock Exchange Website etc., appointed by CSRC.
All directors are attended the Board Meeting for report deliberation.
Prompt of modified auditing opinion
□ Applicable √ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting
period
□ Applicable √ Not applicable
The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves
Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable √ Not applicable
II. Basic information of the company
1. Company profile
Short form of the stock Sinopharm Accord, Accord B Stock code 000028, 200028
Stock exchange for listing Shenzhen Stock Exchange
Person/Way to contact Secretary of the Board Rep. of security affairs
Name Chen Changbing Wang Zhaoyu
Accord Pharm. Bldg., No. 15, Ba Gua Si Accord Pharm. Bldg., No. 15, Ba Gua Si
Office add. Road, Futian District, Shenzhen, Guangdong Road, Futian District, Shenzhen, Guangdong
Province Province
Tel. +(86)755 25875222 +(86)755 25875222
E-mail gyyzinvestor@sinopharm.com gyyz0028@sinopharm.com
2. Main financial data and index
Whether it has retroactive adjustment or re-statement on previous accounting data
1
□ Yes √ No
Increase/decrease in this
Current Period Same period of last year
report y-o-y
Operating revenue (RMB) 36,128,910,049.98 33,163,091,887.39 8.94%
Net profit attributable to shareholders of
674,215,912.93 741,445,013.25 -9.07%
the listed Company (RMB)
Net profit attributable to shareholders of
the listed Company after deducting non- 652,857,302.76 720,954,408.22 -9.45%
recurring gains and losses (RMB)
Net cash flow arising from operating
1,041,664,059.17 1,229,373,283.57 -15.27%
activities (RMB)
Basic earnings per share (RMB/Share)
1.57 1.73 -9.25%
(note 1)
Diluted earnings per share (RMB/Share) 1.57 1.73 -9.25%
Weighted average ROE 4.44% 5.22% 0.78percentage points down
Increase/decrease in this
End of current period End of last period report-end over that of last
period-end (+,-)
Total assets (RMB) 45,968,980,824.57 42,783,682,431.81 7.45%
Net assets attributable to shareholder of
15,342,295,205.24 14,924,938,052.50 2.80%
listed Company (RMB)
3. Number of shareholders and share-holding
Unit: share
Total preference shareholders
Total common shareholders at with voting rights recovered at
43,689 0
period-end end of reporting period (if
applicable)
Top ten shareholders
Information of shares
Full name of Nature of Proportion of Amount of
Amount of restricted shares held pledged, tagged or frozen
Shareholders shareholder shares held shares held
State of share Amount
Sinopharm State-owned
56.06% 239,999,991 5,505,770
Group Co., Ltd. Corporation
FIRST
SENTIER
INVESTORS
GLOBAL
Foreign
UMBRELLA 2.52% 10,802,495
Corporation
FUND PLC -
FSSA CHINA
GROWTH
FUND
2
Hong Kong
Securities Foreign
1.73% 7,415,259
Clearing Corporation
Company Ltd
China National
Pharmaceutical State-owned
1.24% 5,323,043
Foreign Trade Corporation
Corp.
National Social Domestic non
Security Fund state-owned 1.19% 5,100,032
413 Portfolio Corporation
BBH BOS S/A
FIDELITY FD - Foreign
0.78% 3,358,761
CHINA FOCUS Corporation
FD
Fidelity
Investment
Domestic non
Management
state-owned 0.54% 2,301,737
(Hong Kong)
Corporation
Limited -
Client’s fund
CPIC Fund -
China Pacific
Life Insurance
Co., Ltd. - with-
profit insurance-
CPIC Fund
Domestic non
China Pacific
state-owned 0.47% 1,999,227
Life Equity
Corporation
Relative Income
(Guaranteed
Dividend)
single assets
management
plan
ICBC-Guolian
Andesheng
Domestic non
Small Selected
state-owned 0.38% 1,632,000
Securities
Corporation
Investment
Fund
UBS AG
Foreign
LONDON 0.30% 1,271,030
Corporation
BRANCH
3
Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have
Explanation on associated the same actual controller, which is China National Pharmaceutical Group Corporation. It is
relationship among the aforesaid unknown that there exists no associated relationship or belongs to the consistent actionist among
shareholders the other tradable shareholders regulated by the Management Measure of Information Disclosure
on Change of Shareholding for Listed Companies.
4. Changes of controlling shareholders or actual controller
Changes of controlling shareholders in reporting period
□ Applicable √ Not applicable
Changes of controlling shareholders had no change in reporting period.
Changes of actual controller in reporting period
□ Applicable √ Not applicable
Changes of actual controller had no change in reporting period.
5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with
preferred stock held
The Company had no shareholders with preferred stock held in the reporting.
6. Bonds in existence as of the approval date of the semi-annual report
□ Applicable √ Not applicable
III. Important events
On December 29, 2021, Sinopharm Holding Guoda Drugstore Co., Ltd. (hereinafter referred to as "Guoda Drugstore"), a
controlling subsidiary of the Company, entered in to the Letter of Intent for Cooperation on the acquisition of some social retail
pharmacy assets of the Company's controlling shareholders with Sinopharm Holding Hubei Co., Ltd. (hereinafter referred to as
"Sinopharm Holding Hubei"). For details, please refer to the Sinopharm Accord: Announcement on Related Transactions of
Controlling Shareholders' Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social Retail
Pharmacy Assets" (Announcement No.:2021-42) disclosed on www.cninfo.com.cn dated December 31, 2021 .
On June 27, 2022, the seventh meeting of the ninth board of directors of the company reviewed and approved the Proposal on
Sinopharm Holding Guoda Drugstore Co., Ltd. Entrusting 100% Equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co.,
Ltd. and Changing the Way to Solve the Horizontal Competition of Social Retail Pharmacy Assets. The board of directors agreed
that Guoda Drugstore and Sinopharm Holding Hubei sign the Equity Escrow Agreement, changing the original method of solving
the horizontal competition of social retail pharmacy assets from acquisition to escrow, that is, from Guoda Drugstore purchasing
51% equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co., Ltd. to escrowing 100% of its equity. On June 27, 2022, the
4
two parties formally signed the Equity Escrow Agreement. For details, please refer to the Sinopharm Accord: Progress
Announcement on the Controlling Shareholder's Fulfillment of Commitments and Solving the Problem of Horizontal Competition
in Social Retail Pharmacy Assets" (Announcement No.:2022-28) disclosed on www.cninfo.com.cn dated June 29, 2022.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
August 31, 2022
5
